About Sai Life Sciences Limited

Sai Life Sciences Limited is a fully integrated Contract Research, Development and Manufacturing Organisation (CRDMO) specialising in small-molecule new chemical entities. Established in 1999, the company began with medicinal chemistry services before evolving into an end-to-end partner for pharmaceutical and biotechnology companies, supporting them across discovery, development, and commercial manufacturing.

Headquartered in Hyderabad, Sai Life Sciences operates large R&D and manufacturing sites in India, with additional laboratories near key innovation hubs in the US (Greater Boston) and the UK (Manchester), ensuring proximity to clients and offering economical scale-up options.

The company caters to a global innovator client base, including 18 of the world’s top 25 pharmaceutical companies by revenue (CY2024). It serves regulated markets such as the US, Europe, and Japan. By maintaining operations across India, the US, and the UK, Sai Life Sciences ensures smooth technology transfers and scale-ups, while manufacturing activities remain India-based.

The company has three subsidiaries (not named) and achieved several milestones, including successful USFDA and PMDA audits at its facilities, expansion of the Bidar site, and investments in research centres in Boston and Manchester. Sai Life Sciences made its public debut with a stock exchange listing on December 18, 2024, when its equity shares commenced trading on the NSE and BSE.

Business Segment of Sai Life Sciences Limited

CRDMO services – 100% of turnover, covering discovery, development, and commercial manufacturing for small molecules.

Sai Life Sciences Limited’s Key Management Team

• K. Ranga Raju – Chairman

• Krishnam Raju – Managing Director & Chief Executive Officer

• Sivaramakrishnan Chittor – Director & Chief Financial Officer

• Runa Karan – Company Secretary & Compliance Officer

Latest Updates on Sai Life Sciences Limited

• IPO milestone: Sai Life Sciences listed its equity shares on NSE and BSE on December 18, 2024. The IPO was oversubscribed 10.27 times with 39.85 crore bids for 3.87 crore shares. Shares debuted at ₹650 on NSE (18.4% premium) and ₹660 on BSE (20.22% premium).

• Strengthened balance sheet: IPO proceeds were used to repay ₹720 crore of debt, reducing leverage and enabling growth flexibility.

• Facility upgrades: Established a Peptide Research Center at Unit II and commissioned a High Potency API (HPAPI) manufacturing block at Unit IV, Bidar, to support advanced modalities.

• Global footprint: Nearly 97% of revenue comes from international markets, primarily North America, Europe, Japan, and the UK.

• Workforce scale: As of March 31, 2025, the company employed 3,401 permanent staff across domestic and international operations.